Related Experiment Video

Updated: May 1, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

13.1K

Individualization of chronic hepatitis C treatment according to the host characteristics

Nikolaos K Gatselis1, Kalliopi Zachou1, Asterios Saitis1

  • 1Nikolaos K Gatselis, Kalliopi Zachou, Asterios Saitis, George N Dalekos, Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, 41110 Larissa, Greece.

World Journal of Gastroenterology
|March 25, 2014
PubMed

Insights

Hepatitis C virus (HCV) infection impacts millions globally, leading to severe liver disease. Host factors like interleukin-28B are crucial for personalizing HCV treatment strategies.

Area of Science:

  • Hepatology and Virology
  • Immunogenetics
  • Personalized Medicine

Background:

  • Hepatitis C virus (HCV) infection is a significant global health issue affecting over 170 million people.
  • HCV is a leading cause of cirrhosis, hepatocellular carcinoma, liver failure, and transplantation.
  • Recent advancements have identified host factors influencing HCV natural history and treatment response.

Purpose of the Study:

  • To review current knowledge on host factors in Hepatitis C virus infection.
  • To explore the role of specific host factors in individualizing HCV treatment.
  • To summarize the impact of genetic factors on HCV pathogenesis and treatment outcomes.

Main Methods:

  • Literature review of recent studies on Hepatitis C virus (HCV) pathogenesis.
  • Analysis of genome-wide association studies (GWAS) identifying host genetic factors.
  • Synthesis of current understanding of host-pathogen interactions in HCV infection.

Main Results:

  • Host factors, including interleukin-28B and inosine triphosphatase, play a significant role in HCV infection.
  • Genetic variations in host factors influence disease progression and response to antiviral therapy.
  • Understanding these host factors is key to developing personalized treatment approaches.

Conclusions:

  • Host factors are critical determinants of individual outcomes in Hepatitis C virus infection.
  • Personalized treatment strategies for HCV should consider the patient's genetic makeup.
  • Further research into host-pathogen interactions will refine HCV management and improve patient care.

Keywords:
Chronic hepatitis CHepatitis C virus host factorsInosine triphosphataseInterleukin 28BSingle nucleotide polymorphism

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

7.2K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
398
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
220
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379